Impact of a combined multimodal-aerobic and multimodal intervention compared to standard aerobic treatment in breast cancer survivors with chronic cancer-related fatigue - results of a three-armed pragmatic trial in a comprehensive cohort design

Kröz, Matthias; Reif, Marcus; Glinz, Augustina; Berger, Bettina; Nikolaou, Andreas; Zerm, Roland; Brinkhaus, Benno; Girke, Matthias; Büssing, Arndt; Gutenbrunner, Christoph

doi:10.1186/s12885-017-3142-7

Table 4 Differences from baseline values at T1 and T2

From: Impact of a combined multimodal-aerobic and multimodal intervention compared to standard aerobic treatment in breast cancer survivors with chronic cancer-related fatigue - results of a three-armed pragmatic trial in a comprehensive cohort design

	Aerobic therapy	Multimodal therapy	p	Combination therapy	p
CFS-D total score
T1.10-T0.01	−6.3 (7.4)	−8.9 (7.1)^†	0.053	−7.9 (9.0)	0.285
T2-T0.01	−3.4 (9.1)	−9.1 (7.9) ^††	0.004	−7.3 (10.2)	0.111
PSQI total score
T1.10-T0.01	−1.0 (1.8)	−2.9 (2.9) ^††	0.044	−2.5 (3.4)	0.077
T2-T0.01	−0.3 (2.8)	−2.4 (4.0) ^†	0.047	−3.1 (3.2)	0.007
CFS-D physical
T1.10-T0.01	−3.2 (3.8)	−3.7 (3.5)	0.359	−3.2 (4.2)	0.777
T2-T0.01	−0.9 (4.1)	−4.1 (4.2) ^††	0.003	−3.1 (4.6)	0.075
CFS-D cognitive
T1.10-T0.01	−2.0 (2.3)	−3.0 (3.1)^†	0.062	−2.5 (3.1)	0.556
T2-T0.01	−2.0 (3.6)	−2.9 (3.2)^†	0.055	−2.6 (3.7)	0.431
CFS-D affective
T1.10-T0.01	−1.1 (1.9)	−2.2 (2.0) ^††	0.004	−2.2 (2.6)	0.018
T2-T0.01	−0.5 (2.1)	−2.2 (1.7) ^†††	0.004	−1.6 (3.4)	0.079
PSQI subjective sleep quality
T1.10-T0.01	−0.5 (0.5)	−0.6 (0.6)	0.842	−0.5 (0.8)	0.757
T2-T0.01	−0.1 (0.7)	−0.6 (0.8)^†	0.054	−0.7 (0.7)	0.041
PSQI sleep latency
T1.10-T0.01	0.0 (0.8)	−0.7 (0.9) ^††	0.004	−0.3 (0.8)	0.066
T2-T0.01	0.1 (0.8)	−0.4 (1.0)	0.155	−0.4 (1.1)	0.0296
PSQI sleep duration
T1.10-T0.01	−0.5 (0.7)	−0.2 (0.8)	0.497	−0.2 (1.0)	0.517
T2-T0.01	−0.1 (0.6)	−0.4 (1.2)	0.226	−0.6 (1.1)	0.036
PSQI sleep efficiency
T1.10-T0.01	−0.3 (0.8)	−0.7 (1.3)	0.258	−0.6 (1.1)	0.335
T2-T0.01	0.1 (1.0)	−0.3 (1.3)	0.759	−0.7 (1.1)	0.0597
PSQI sleep disturbances
T1.10-T0.01	−0.1 (0.3)	−0.3 (0.6)	0.411	−0.2 (0.6)	0.463
T2-T0.01	−0.1 (0.6)	−0.3 (0.6)	0.2497	−0.1 (0.7)	0.397
PSQI taking hypnotics
T1.10-T0.01	0.3 (0.9)	−0.1 (0.5)^†	0.109	−0.1 (0.6)	0.109
T2-T0.01	−0.1 (0.9)	0.1 (0.6)	0.398	−0.1 (0.6)	0.637
PSQI daytime sleepiness
T1.10-T0.01	−0.3 (0.8)	−0.5 (0.7)^†	0.066	−0.5 (0.6)	0.326
T2-T0.01	−0.2 (0.7)	−0.5 (0.8) ^††	0.024	−0.5 (0.8)	0.180

p-value for test for superiority vs. aerobic therapy
^†test for non-inferiority vs. aerobic therapy
Mean (SD); ^† p < 0.05, ^†† p < 0.01; ^††† p < 0.001

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us